Summary: A fresh secondary analysis of the PANDA clinical trial shows that sertraline — one of the most widely prescribed antidepressants — produces measurable improvement in core emotional symptoms of depression, including sadness, self-loathing and suicidal thoughts, within two weeks of starting treatment. By applying network analysis to individual symptoms, researchers also observed early reductions in anxiety, while physical or somatic effects such as fatigue and reduced libido emerged early but levelled off after several weeks.
These results provide a more detailed understanding of how antidepressants affect emotional versus physical symptoms, suggesting that some patients may experience meaningful relief sooner than previously understood.
Key Facts
- Early Emotional Relief: Sertraline reduced core emotional symptoms — mood, anxiety and suicidal thoughts — within two weeks.
- Side Effects Stabilize: Physical side effects like low libido, tiredness and sleep disruption increased early but tended to stabilise after six weeks.
- Symptom-Level Insight: Network analysis reveals that sertraline’s effects vary between emotional and somatic symptoms rather than acting uniformly across all depressive symptoms.
Source: UCL
Overview
A new symptom-level analysis of data from the PANDA trial — led by researchers at University College London and published in Nature Mental Health — indicates that sertraline can alleviate several core symptoms of depression and anxiety within two weeks of treatment. The PANDA trial originally reported results in 2019, noting early benefits for anxiety but slower change in overall depression scores. This reanalysis uses network models to examine how individual symptoms change over time, revealing a more nuanced picture.
Network analysis treats depression and anxiety as clusters of interacting symptoms rather than single, homogeneous disorders. This approach allowed the team to identify distinct treatment effects across specific symptoms: emotional symptoms such as sadness, self-criticism, restlessness and suicidal thoughts improved early, while some somatic symptoms — including decreased libido, poor sleep and tiredness — worsened initially, likely reflecting side effects that can also be features of depression.
The PANDA trial was a randomized controlled study assessing sertraline in people in England with a wide range of depressive symptoms, from mild to moderate. The original 2019 Lancet Psychiatry report showed improvement in anxiety and overall mental health by six weeks, with meaningful changes in depressive symptoms emerging around 12 weeks. The current network-based reanalysis focused on 571 participants who had complete symptom data at each measurement point, enabling a detailed look at timing and symptom-specific effects.
Findings show that emotional and anxiety symptoms began to improve as early as two weeks after starting sertraline. Somatic symptoms tended to worsen in the short term but reached a plateau after about six weeks. From six to 12 weeks, emotional and anxiety symptoms continued to improve while the somatic side effects remained stable, suggesting the early adverse physical effects may be offset by later emotional gains.
Lead author Dr Giulia Piazza (UCL Psychiatry and UCL Psychology & Language Sciences) explained that this work paints a more complex and clinically relevant picture of sertraline’s effects: “Rather than treating depression and anxiety as single, uniform conditions, network analysis recognises they are constellations of symptoms that can influence one another over time. For example, poor sleep can lead to trouble concentrating, which may affect self-esteem. Our approach provides richer insight into which symptoms respond earlier to treatment.”
Co-author Professor Glyn Lewis (UCL Psychiatry), who led the PANDA trial, said the findings strengthen the evidence supporting sertraline for people with depressive and anxiety symptoms and will help clinicians and patients make better-informed treatment decisions. Co-senior author Professor Jean-Baptiste Pingault (UCL Psychology & Language Sciences) added that detecting beneficial effects as early as two weeks highlights the value of examining symptom-level responses when evaluating psychiatric treatments.
Clinical implications
These results emphasise the importance of monitoring symptoms individually rather than relying solely on aggregate depression scores. Clinicians should be aware that emotional relief may appear quickly for some patients, while somatic side effects can emerge early and stabilise after a few weeks. Understanding these differing timelines may improve shared decision-making, adherence and expectations around recovery.
Funding: The study was supported by Wellcome. The PANDA trial received funding from the National Institute for Health Research (NIHR) and the NIHR University College London Hospitals Biomedical Research Centre.
Key Questions Answered:
A: Emotional symptoms such as sadness and anxiety showed improvement within two weeks, earlier than commonly assumed.
A: Participants reported somatic effects including tiredness, reduced libido and sleep disturbances, which tended to stabilise after about six weeks.
A: By examining symptoms individually, the study shows antidepressants can have uneven effects across emotional and physical symptoms, offering insights that may guide more tailored treatment strategies.
About this antidepressant research news
Author: Chris Lane
Source: UCL
Contact: Chris Lane – UCL
Image: The image is credited to Neuroscience News
Original Research: Open access.
“The effect of sertraline on networks of mood and anxiety symptoms: secondary analysis of the PANDA randomized controlled trial” by Giulia Piazza et al. Nature Mental Health
Abstract
The effect of sertraline on networks of mood and anxiety symptoms: secondary analysis of the PANDA randomized controlled trial
Depression is a heterogeneous condition composed of many possible symptom combinations, yet clinical trials frequently treat it as a single, uniform outcome. This study adopts a symptom-level perspective to evaluate how the selective serotonin reuptake inhibitor sertraline affects individual symptoms of depression and anxiety and the relationships among them.
Using data from the PANDA randomized controlled trial, the researchers built network models to estimate sertraline’s effects at different time points (contemporaneous networks at two, six and 12 weeks) and across time (temporally lagged networks). Results demonstrate beneficial effects on core emotional symptoms and anxiety as early as two weeks, counterbalanced by adverse effects on somatic symptoms. This complex pattern is often hidden when depression is measured as a single dimension.
Focusing on individual symptoms may clarify the timing, nature and mechanisms of antidepressant action and help improve how treatments are evaluated and developed in psychiatry.